iwCLL 2023

CME

Jointly provided by:

Target Audience

This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who care for patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be able to::
  • (YIM) Evaluate and interpret the clinical significance of emerging evidence regarding:
    • Factors contributing to the development of CLL
    • The diagnosis, prognosis, and initial treatment of CLL
    • Factors contributing to disease evolution and progression
    • Treatment of advanced disease
  • Evaluate the clinical trial results of current and emerging treatment strategies for patients with newly diagnosed CLL
  • Assess the latest safety and efficacy data of novel agents for patients with relapsed/refractory CLL
  • Identify best practices to achieve optimal outcomes among patients with CLL, including treating patients with high-risk disease, minimizing adverse events, and achieving minimal residual disease negativity
  • Discuss how genomics, proteomics, and metabolism of CLL affect the pathogenesis of disease
  • Compare and contrast approaches to the treatment of patients who develop Richter’s transformation
  • Recognize unique patient factors that influence the care of patients with CLL, including immunodeficiency and the risk of infections
  • Examine global perspectives and approaches for caring for patients with CLL

Faculty

https://iwcll2023.org/program/iwcll-faculty/

Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Program Agenda

https://iwcll2023.org/program/iwcll-program/

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact Sarah Rowan prior to the live event at iwCLLBoston@BioAscend.com

Fee Information

https://iwcll2023.org/registration/

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), Bio Ascend, LLC and iwCLL. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

This activity has been approved for AMA PRA Category 1 Credit(s)™.

International Physicians

The UEMS-EACCME® has had an agreement of mutual recognition of credits with the American Medical Association (AMA) for live educational events and for e-learning materials since the year 2000. The agreement was renewed in 2022 for another 4 years. Upon completion of this activity, PACE will provide European physicians with a certificate of completion that lists the number of AMA PRA Category 1 Credits™ and a statement that refers to the AMA agreement with the EACCME.